Strategic Neurodelivery of Psychedelic Compounds: Bridging Molecular Pharmacology with Therapeutic Innovation in CNS Disorders.
CNS Neurol Disord Drug Targets March 11, 2026 Shikha Baghel Chauhan, Naziya Akhtar, Chirag Jain et al.
This work explores how psychedelic compounds can be delivered to the brain more effectively to treat central nervous system disorders. It bridges molecular pharmacology with therapeutic innovation by discussing strategies for targeted neurodelivery, aiming to enhance efficacy and reduce side effects. The paper reviews current understanding of how psychedelics interact with neural targets and proposes methods to optimize their transport across the blood-brain barrier. The goal is to improve clinical outcomes for conditions such as depression, anxiety, and addiction by ensuring that these compounds reach the right brain regions in the right amounts.